Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

COGT

Cogent Biosciences (COGT)

Cogent Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:COGT
日付受信時刻ニュースソース見出しコード企業名
2024/06/1420 : 30GlobeNewswire Inc.Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)NASDAQ:COGTCogent Biosciences Inc
2024/06/1408 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/06/1408 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/06/1408 : 11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/06/1408 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/06/1319 : 06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/06/1310 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/06/0605 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/05/3005 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/05/3005 : 01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/05/2406 : 05GlobeNewswire Inc.Cogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerNASDAQ:COGTCogent Biosciences Inc
2024/05/2406 : 01GlobeNewswire Inc.Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual MeetingNASDAQ:COGTCogent Biosciences Inc
2024/05/0721 : 26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
2024/05/0721 : 19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/05/0721 : 00GlobeNewswire Inc.Cogent Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
2024/04/0922 : 00GlobeNewswire Inc.Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorNASDAQ:COGTCogent Biosciences Inc
2024/02/2706 : 34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:COGTCogent Biosciences Inc
2024/02/2623 : 13Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:COGTCogent Biosciences Inc
2024/02/2622 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/02/2622 : 00GlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
2024/02/2304 : 30GlobeNewswire Inc.Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisNASDAQ:COGTCogent Biosciences Inc
2024/02/1708 : 55Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/02/1708 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
2024/02/1506 : 05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/02/1502 : 51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:COGTCogent Biosciences Inc
2024/02/1422 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
2024/02/1421 : 00GlobeNewswire Inc.Cogent Biosciences Announces Oversubscribed $225 Million Private PlacementNASDAQ:COGTCogent Biosciences Inc
2024/02/1006 : 22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
2024/02/0523 : 00GlobeNewswire Inc.Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingNASDAQ:COGTCogent Biosciences Inc
2024/01/2606 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:COGT

最近閲覧した銘柄

Delayed Upgrade Clock